PepGen Faces Clinical Hold on Lead DM1 Program, Discontinues DMD Program, and Reports Dilutive $107.6M Offering

summarizeSummary

PepGen announced a partial clinical hold on its lead DM1 drug candidate, discontinued its DMD program, and completed a highly dilutive $107.6 million equity offering, alongside repricing executive stock options.

check_boxKey Events

• Partial Clinical Hold on Lead DM1 Program

  The FDA placed a partial clinical hold on the Phase 2 FREEDOM2 trial for PGN-EDODM1, citing concerns from previously submitted preclinical pharmacology and toxicology studies. This follows the recent unblinding of Phase 1 data which showed transient kidney biomarkers at higher doses.

• Discontinuation of DMD Program

  The company voluntarily discontinued the development of PGN-EDO51 for Duchenne muscular dystrophy (DMD) and wound down all related R&D activities in May 2025, after the CONNECT1 Phase 2 trial did not achieve target dystrophin levels.

• Significant Dilutive Equity Offering

  In September 2025, PepGen completed a public offering of 35,937,500 shares at $3.20 per share, raising net proceeds of $107.6 million. This follows a $86.3 million raise in February 2024 from an ATM program and another offering.

• Executive Stock Option Repricing

  On November 4, 2025, the board approved repricing 3,557,903 employee stock options with exercise prices ranging from $8.89-$17.91 down to $4.53 per share, resulting in $3.4 million in incremental stock-based compensation expense.

auto_awesomeAnalysis

PepGen Inc. is facing significant setbacks with a partial clinical hold on its lead drug candidate, PGN-EDODM1, for Myotonic Dystrophy Type 1 (DM1), due to preclinical concerns. This comes after the company already discontinued its PGN-EDO51 program for Duchenne Muscular Dystrophy (DMD) in May 2025 due to insufficient efficacy. To extend its operational runway into the second half of 2027, the company completed a highly dilutive public offering in September 2025, raising $107.6 million. Further compounding shareholder concerns, the board approved a repricing of over 3.5 million employee stock options to a significantly lower exercise price of $4.53, indicating efforts to re-incentivize employees amidst these challenges. These events collectively signal increased risk and uncertainty regarding PepGen's pipeline and financial stability.